Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma

Chimeric SF-25 monoclonal antibody as a targeted therapy for SLC3A2 in adult T-cell leukemia/lymphoma

Abstract The SF-25 antigen (SF-25 Ag), which functions as the amino acid transporter solute carrier family 3 member 2 (SLC3A2), is essential for regulatory T (Treg) cell maintenance and is highly expressed in adult T-cell leukemia/lymphoma (ATL) cells. We analyzed SF-25 Ag expression in CD4+peripher...

Full description

Saved in:
Bibliographic Details
Main Authors: Shinsuke Suzuki, Xiao-Yan Lin, Shuichi Hanada, Kimiharu Uozumi, Maki Otsuka, Satsuki Owatari, Koichi Haraguchi, Makoto Yoshimitsu, Kenji Ishitsuka, Hiroshi Takahashi
Format: Article
Language:English
Published: Nature Portfolio 2025-08-01
Series:Scientific Reports
Subjects:
SF-25 Ag
SLC3A2
HTLV-1
Adult T-cell leukemia/lymphoma
Magnetic cell sorting
c-SF-25 Mab
Online Access:https://doi.org/10.1038/s41598-025-14572-1
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The SF-25 antigen (SF-25 Ag), which functions as the amino acid transporter solute carrier family 3 member 2 (SLC3A2), is essential for regulatory T (Treg) cell maintenance and is highly expressed in adult T-cell leukemia/lymphoma (ATL) cells. We analyzed SF-25 Ag expression in CD4+peripheral blood lymphocytes (PBLs) from 28 ATL patients, 52 healthy human T-lymphotropic virus 1 (HTLV-1) carriers, and eight non-infected individuals. Inverse polymerase chain reaction was used to detect monoclonal integration of HTLV-1 proviral DNA. The median (interquartile range) percentages of SF-25 Ag-positive PBLs in acute, chronic, and smoldering ATL were 54.9% (23.9–62.9), 34.9% (23.8–41.9), and 22.1% (8.4–28.5), respectively, which were significantly higher than those in HTLV-1 carriers (0.8% [0.5–1.0]) and non-infected subjects (0.4% [0.3–0.4]) (P < 0.001). Magnetic sorting isolated SF-25 Ag-positive cells, which showed monoclonal HTLV-1 integration, unlike SF-25 Ag-negative cells. Moreover, culture supernatant from healthy donor PBLs stimulated with a murine-human chimeric SF-25 monoclonal antibody (c-SF-25 Mab) induced apoptosis in SF-25 Ag-positive ATL cells. These findings suggest that c-SF-25 Mab, by targeting SLC3A2, may offer a specific therapeutic approach for ATL by eliminating malignant cells while sparing normal tissue.
ISSN:2045-2322

Similar Items